Challenges and opportunities in stewardship among solid organ transplant recipients with Candida auris bloodstream infections
Abstract
Background: Candida auris is an emerging nosocomial pathogen worldwide. However, there has been little published on the management of C. auris in solid organ transplant recipients. Methods: A single‐center, retrospective cohort study was conducted to evaluate C. auris bloodstream infections in solid organ transplant recipients between January 2020 and December 2021. Patient‐related and outcomes data were extracted from electronic medical records. Results: Of the 42 patients identified with C. auris bloodstream infections, five were in solid organ transplant recipients (1 heart, 3 liver, and 1 combined liver‐kidney). The median time to fungemia from hospital admission was 43 days, and the median time to fungemia from transplant was 18 days. All patients received micafungin as initial treatment, at a median of 6 hours from pathogen detection. Four patients achieved blood clearance, two patients had persistent fungemia, and two patients developed secondary complications from hematogenous spread. One patient died, resulting in a mortality rate of 20%. Conclusions: Solid organ transplant recipients are at high risk for developing C. auris bloodstream infections. In order to prevent graft loss and mortality, best practices for the management of C.auris should include rapid screening, diagnosis, and treatment. While echinocandins are considered first‐line, antifungal selection should be based on susceptibilities and site of infection. Data to support routine use of combination therapy are lacking, however there may be a role for refractory cases. Prevention efforts against C. auris infection are especially important given the lack of effective decolonization strategies. For transplant recipients, hospitals should seek opportunities to restore patients' gut microbiome by curtailing unnecessary hospital procedures and inappropriate antimicrobial use. Further research and national guidelines are needed to better direct stewardship in this field.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
C. auris is an emerging fungal pathogen that can cause serious human infections.
“C. auris is an emerging fungal pathogen that can cause serious human infections [1,5,38,39].”
From The Emerging Fungal Pathogen Candida auris Induces IFNγ to Colonize the Skin (2025) · cites this paper as [38]
C. auris is an emerging multi-drug-resistant fungal pathogen that can cause fatal infections in humans.
“C. auris is an emerging multi-drug-resistant fungal pathogen that can cause fatal infections in humans (1, 19, 20).”
From Differential skin immune responses in mice intradermally infected with <i>Candida auris</i> and <i>Candida albicans</i> (2023) · cites this paper as [19]
The citation lists haven’t been fetched yet
References 20 · Cited by 23
- Authors
- Vu, C. A., Jimenez, A., Anjan, S., & Abbo, L. M.
- Affiliations
- Jackson Memorial Hospital (US)
- Department of Infection Prevention and Control Jackson Health System Miami Florida USA
- University of Miami (US)
- Corresponding author
- Vu, Christine A.
- Venue
- Transplant Infectious Disease
- Publisher
- Wiley
- Published
- 2022-10
- Volume
- 24
- Issue
- 5
- Pages
- e13919-e13919
- ISSN
- 1398-2273 (ISSN-L)
- 1399-3062
- OpenAlex
- W4306682494
- Cited by
- 23
- References
- 20
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplant Infectious Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
- Keywords
- Candida auris, bloodstream infection, solid organ transplant recipients, antifungal stewardship, micafungin, echinocandins, fungemia, decolonization, gut microbiota, antimicrobial use, nosocomial infections, heart transplantation, liver transplantation
- MeSH terms
- Micafungin, Candida auris, Antifungal Agents, Candida, Humans, Retrospective Studies, Organ Transplantation, Fungemia, Echinocandins, Candidiasis, Invasive, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review